Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Express Scripts
Johnson and Johnson
Medtronic
Mallinckrodt

Last Updated: May 28, 2022

Investigational Drug Information for VS-6063


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for VS-6063?

VS-6063 is an investigational drug.

There have been 18 clinical trials for VS-6063. The most recent clinical trial was a Phase 2 trial, which was initiated on August 12th 2015.

The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, and Lung Neoplasms. The leading clinical trial sponsors are Verastem, Inc., National Cancer Institute (NCI), and Merck Sharp & Dohme Corp.

There are seventeen US patents protecting this investigational drug and two hundred and one international patents.

Recent Clinical Trials for VS-6063
TitleSponsorPhase
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas AdenocarcinomaNational Cancer Institute (NCI)Phase 2
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas AdenocarcinomaVerastem, Inc.Phase 2
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas AdenocarcinomaWashington University School of MedicinePhase 2

See all VS-6063 clinical trials

Clinical Trial Summary for VS-6063

Top disease conditions for VS-6063
Top clinical trial sponsors for VS-6063

See all VS-6063 clinical trials

US Patents for VS-6063

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
VS-6063 See Plans and Pricing Gene fusions and gene variants associated with cancer LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA) See Plans and Pricing
VS-6063 See Plans and Pricing Methods of diagnosing and treating B cell acute lymphoblastic leukemia The General Hospital Corporation (Boston, MA) Tufts Medical Center, Inc. (Boston, MA) See Plans and Pricing
VS-6063 See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
VS-6063 See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for VS-6063

Drugname Country Document Number Estimated Expiration Related US Patent
VS-6063 Australia AU2014254394 2033-04-17 See Plans and Pricing
VS-6063 China CN105378110 2033-04-17 See Plans and Pricing
VS-6063 China CN106414768 2033-04-17 See Plans and Pricing
VS-6063 European Patent Office EP2986736 2033-04-17 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Express Scripts
Johnson and Johnson
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.